SCHEMBL29967752

SCHEMBL29967752

NC(=O)c1ccc(N2CCN(Cc3ccccc3)CC2)c(NC(=O)Nc2ccccc2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.53
MAPT P10636 3/20 0.53
TP53 P04637 4/20 0.52
LMNA P02545 1/20 0.52
RAB9A P51151 3/20 0.52
NPC1 O15118 2/20 0.52
POLB P06746 1/20 0.52
NPY2R P49146 1/20 0.49
FAAH O00519 1/20 0.49
BACE1 P56817 2/20 0.48
SRPK1 Q96SB4 1/20 0.48
PRMT1 Q99873 1/20 0.48
DRD2 P14416 1/20 0.48
DRD4 P21917 1/20 0.48
DRD3 P35462 1/20 0.48
KMT2A Q03164 1/20 0.48
HDAC3 O15379 1/20 0.47
HDAC4 P56524 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC7 Q8WUI4 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6684996 1.00 KDM4E (0.53) KDM4EMAPTTP53LMNARAB9A
SCHEMBL29968547 0.84 CCR3 (0.55) KDM4EMAPTTP53LMNAPOLB
SCHEMBL6799649 0.84 CCR3 (0.55) KDM4EMAPTTP53LMNAPOLB
SCHEMBL6694739 0.84 KMT2A (0.49) KDM4EMAPTTP53LMNARAB9A
SCHEMBL6686127 0.81 MAPT (0.51) KDM4EMAPTTP53LMNAPOLB
SCHEMBL29968131 0.81 MAPT (0.51) KDM4EMAPTTP53LMNAPOLB
SCHEMBL6687418 0.80 TP53 (0.66) KDM4EMAPTTP53LMNARAB9A
SCHEMBL29968981 0.80 TP53 (0.66) KDM4EMAPTTP53LMNARAB9A
SCHEMBL29968476 0.80 LMNA (0.51) KDM4EMAPTTP53LMNARAB9A
SCHEMBL6797486 0.80 PARP14 (0.50) KDM4EMAPTTP53LMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117999073-A Use of nadolol to treat chronic obstructive pulmonary disease by blocking the inhibitor protein-2 pathway 慢性呼吸道治疗有限公司 2024-05-07 CN disclosed
EP-4304717-A1 USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY Chronic Airway Therapeutics Limited (AU) 2024-01-17 EP disclosed
WO-2022192252-A1 USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) 2022-09-15 WO disclosed